Abstract: A computer-implemented method and system for transforming a trained artificial intelligence (AI) model into a trustworthy artificial intelligence model, wherein the trained AI model is provided via a user interface of a webservice platform, a validation data set based on training data of the trained artificial intelligence model is provided, generic samples are generated by a computing component of the webservice platform based on the validation data set, the trained artificial intelligence model is transformed by optimizing a calibration based on the generic samples, where the transformation of the artificial intelligence model is performed by a computing component of the web service platform, and the input, i.e. the trained artificial intelligence model and a validation data set, is provided therefor to the computing component via a user interface of the web service platform.

Abstract: An integrated starter and on-board electrical system disconnecting module for connecting to a starter battery and to an on-board electrical system by a transducer is disclosed. A method for limiting the starting current in a motor vehicle and the use of the integrated starter and on-board electrical system disconnecting module in multi-voltage on-board electrical systems, in particular during a start-stop operation of plug-in hybrid vehicles and for hybrid on-board electrical systems, are also disclosed. The transducer can be connected to a starter circuit including the starter battery from an on-board electrical system side, via a starter control device and via an on-board electrical system disconnector. The on-board electrical system can be uncoupled from the starter circuit and the starter control device and the on-board electrical system disconnector are integrated in the module.

Abstract: The invention is directed to a pharmaceutical composition comprising a progesterone receptor antagonist namely (11?,17?)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one for the treatment and/or prophylaxis of Uterine Fibroids (myomas, uterine leiomyoma) that is administered to a patient diagnosed with Uterine Fibroids following a specific regimen. Additionally, the invention is directed to a method for treating Uterine Fibroids (myomas, uterine leiomyoma) and/or for reducing Uterine Fibroids (myomas, uterine leiomyoma) size and symptoms related to Uterine Fibroids following a specific regimen as well as treatment of Heavy Menstrual Bleeding (HMB).

Abstract: A motor vehicle includes a body having a front apron, and an underbody. The body forms at least one left and one right front wheel house for receiving one front wheel each. The air-guiding devices have at least one left flow duct and at least one right flow duct. The at least one left flow duct opens in the underbody in front of the left wheel house. The at least one right flow duct opens in the underbody in front of the right wheel house. The respective exit opening is arranged in front of that region of the respective wheel house which is adjacent to the inner side, which faces the vehicle central plane, of the respective vehicle wheel in the straight-ahead position.

Abstract: The invention is directed to a pharmaceutical composition comprising a progesterone receptor antagonist namely (11?, 17?)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one for the treatment and/or prophylaxis of Uterine Fibroids (myomas, uterine leiomyoma) that is administered to a patient diagnosed with Uterine Fibroids following a specific regimen. Additionally, the invention is directed to a method for treating Uterine Fibroids (myomas, uterine leiomyoma) and/or for reducing Uterine Fibroids (myomas, uterine leiomyoma) size and symptoms related to Uterine Fibroids following a specific regimen as well as treatment of Heavy Menstrual Bleeding (HMB).

Abstract: The present invention is related to Selective Progesterone Receptor Modulators (SPRM) as described and defined herein, and covers the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of sexual hormone dependent diseases and gynaecological diseases in particular Endometriosis or Uterine Fibroids (UF), as a sole agent or in combination with other active ingredients wherein circulating endogenous estradiol concentration of treated women is maintained to a level in a range of 40 pg/mL to 85 pg/mL.

Abstract: The present invention provides an extracellular anti-linker/label epitope chimeric antigen receptor (anti-LLE CAR) comprising I) a linker/label epitope (LLE) binding domain, II) a transmembrane domain, and III) a signal transduction domain, wherein said extracellular LLE binding domain binds a target cell binding molecule (TCBM) comprising i) an antigen binding moiety (ABM), wherein said ABM binds specifically to an antigen expressed on a target cell, ii) a label moiety (LaM), wherein said LaM is a naturally occurring molecule in a subject or a derivative thereof, iii) a linker moiety (LiM) conjugating said ABM and said LaM, thereby forming a linker/label epitope (LLE), wherein said extracellular LLE binding domain binds said LLE with a higher preference than said naturally occurring molecule.

Abstract: The invention is directed to a pharmaceutical composition comprising a progesterone receptor antagonist namely (11?,17?)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one for the treatment and/or prophylaxis of Uterine Fibroids (myomas, uterine leiomyoma) that is administered to a patient diagnosed with Uterine Fibroids following a specific regimen. Additionally, the invention is directed to a method for treating Uterine Fibroids (myomas, uterine leiomyoma) and/or for reducing Uterine Fibroids (myomas, uterine leiomyoma) size and symptoms related to Uterine Fibroids following a specific regimen as well as treatment of Heavy Menstrual Bleeding (HMB).

Abstract: The present invention is related to Selective Progesterone Receptor Modulators (SPRM) as described and defined herein, and covers the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of sexual hormone dependent diseases and gynaecological diseases in particular Endometriosis or Uterine Fibroids (UF), as a sole agent or in combination with other active ingredients wherein circulating endogenous estradiol concentration of treated women is maintained to a level in a range of 40 pg/mL to 85 pg/mL.

Abstract: The invention is directed to a pharmaceutical composition comprising a progesterone receptor antagonist namely (11?,17?)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethy)estra-4,9-dien-3-one for the treatment and/or prophylaxis of Uterine Fibroids (myomas, uterine leiomyoma) that is administered to a patient diagnosed with Uterine Fibroids following a specific regimen. Additionally, the invention is directed to a method for treating Uterine Fibroids (myomas, uterine leiomyoma) and/or for reducing Uterine Fibroids (myomas, uterine leiomyoma) size and symptoms related to Uterine Fibroids following a specific regimen as well as treatment of Heavy Menstrual Bleeding (HMB).

Abstract: A motor vehicle includes a body having a front apron, and an underbody. The body forms at least one left and one right front wheel house for receiving one front wheel each. The air-guiding devices have at least one left flow duct and at least one right flow duct. The at least one left flow duct opens in the underbody in front of the left wheel house. The at least one right flow duct opens in the underbody in front of the right wheel house. The respective exit opening is arranged in front of that region of the respective wheel house which is adjacent to the inner side, which faces the vehicle central plane, of the respective vehicle wheel in the straight-ahead position.

Abstract: A product may be provided with a product sensor, thus making it possible to determine, together with the product, data relating to a system or a machine with the aid of the product sensor. The data determined can be used to diagnose and/or control the system or machine. In this case, it is advantageous that the data are obtained at the location of the product and it is thus possible to directly determine a desirable or undesirable effect (for example of environmental parameters or of the system itself) on the product. This system can be used, for example, in automation, in systems or machines or in different product manufacture variants.

Abstract: A method for evaluating component-related energy models and external specification parameters, in order, based on these, to produce a determination of a set of partial-load conditions, which are simulated based on a parameterizable simulation model of the system. A system planner is put in a position, with the specification of specification parameters, for example, a minimum throughput of the system or a maximum energy consumption, in which he can obtain a set of partial-load conditions, i.e., a partial-load condition for each of the components involved in the determination. In this way, an individual partial-load condition can be set for each component, where all the partial-load conditions fulfill the provisions of the specification parameters.

Abstract: Operating status transitions of production plants according to the PROFIEnergy standard are increasingly provided for the energy management of an individual component within a plant. The definition of an operating status change for an individual component leaves unsolved the problem as to how an operating status change of a plant having multiple components is to be effected. Thus, methods and systems that support an automatic operating status change of a plant consisting of a multiplicity of components are provided herein.

Abstract: An underbody trim for the rear-end region of a motor vehicle conceals a rear exhaust muffler. For the purposes of cooling the rear exhaust muffler, an air inlet is provided in the underbody trim. The air inlet is arranged in a region in which, while the motor vehicle is traveling, a pressure is higher at the underside of the underbody trim than the region of the floor panel arranged thereabove. Cooling ambient air is thus conducted into the region of the rear exhaust muffler with low flow losses.

Abstract: The present invention relates to methods of diagnosing, treating, and monitoring endometriosis utilizing patient reported outcome instruments.

Abstract: The use of imidazolium salts (I) where R1 and R3 are each independently an organic radical having 1 to 3000 carbon atoms, R2, R4 and R5 are each independently hydrogen or an organic radical having 1 to 3000 carbon atoms, X is an anion and n is the number 1, 2 or 3 as additives for fuels, especially as detergent additives for diesel fuels, as wax antisettling additives for middle distillate fuels and as lubricity improvers, and for improving the use properties of mineral and synthetic nonaqueous industrial fluids.

Abstract: An underbody trim for the rear-end region of a motor vehicle conceals a rear exhaust muffler. For the purposes of cooling the rear exhaust muffler, an air inlet is provided in the underbody trim. The air inlet is arranged in a region in which, while the motor vehicle is traveling, a pressure is higher at the underside of the underbody trim than the region of the floor panel arranged thereabove. Cooling ambient air is thus conducted into the region of the rear exhaust muffler with low flow losses.

Abstract: A product may be provided with a product sensor, thus making it possible to determine, together with the product, data relating to a system or a machine with the aid of the product sensor. The data determined can be used to diagnose and/or control the system or machine. In this case, it is advantageous that the data are obtained at the location of the product and it is thus possible to directly determine a desirable or undesirable effect (for example of environmental parameters or of the system itself) on the product. This system can be used, for example, in automation, in systems or machines or in different product manufacture variants.

Abstract: A method clusters a plurality of users in a mobile network, according to a specific profile. Data regarding the user is allocated to each user. Data is immediately exchanged between at least two users as soon as said users are located in a predefined communication range in order to spot users with profiles having a given content.